China Yongxin Pharmaceuticals, Inc. (fka CYXN)

[Bobwins]

reverse split. More shareholder friendly actions.....NOT!

Reverse Stock Split

Effective on May 24, 2010, China Yongxin Pharmaceuticals Inc. (the "Company") effectuated a reverse stock split with a ratio of 1-for-12, whereby each twelve
(12) issued and outstanding shares of the common stock of the Company, par value $0.001 per share ("Common Stock") shall be combined into one (1) share of Common Stock (the "Reverse Split"), pursuant to the Certificate of Amendment of the Certificate of Incorporation that the Company filed with the State of Delaware's Secretary of State ("Certificate of Amendment"). As described more fully in the Definitive Information Statement filed by the Company with the Securities and Exchange Commission ("SEC") on February 22, 2010, a reverse split of the Common Stock, with a ratio within a range of 1-for-10 to 1-for-15 (the "Reverse Split Range") and with the exact ratio within the Reverse Split Range to be determined by the Company's Board of Directors (the "Board"), was adopted and approved by written consent dated February 8, 2010 by the Board, the holders of a majority of the shares of Common Stock and Series A Convertible Preferred Stock ("Series A Preferred Stock") then outstanding and entitled to vote (voting as a single class), and by the holders of a majority of our Series A Preferred Stock voting as a separate class. On April 28, 2010, the Board adopted and approved by written consent a 1-for-12 reverse split ratio and it authorized the Company's officers to file the Certificate of Amendment and take all other necessary steps in order to effect the Reverse Split.

Effective May 26, 2010, the Company's Common Stock will commence trading under a new OTC Bulletin Board trading symbol, "CYXND". The new trading symbol has been assigned by Financial Industry Regulatory Authority ("FINRA") in connection with the approval of the Reverse Split. The Company's trading symbol will revert to "CYXN" within 20 business days. The Company's Common Stock, on a split-adjusted basis, has a new CUSIP number of 16946Y 207. The Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K ("Form 8-K") and incorporated herein by reference.

Bylaws Amendments